Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CBIO
CRESCENT BIOPHARMA, INC.
NASDAQ
$17.75
▼ DOWN 0.06% (-0.01)

KEY STATISTICS

Market Cap$659.30 M
52w High$27.41
52w Low$8.72
Dividend Yield—
Frequency—
P/E-1.63
Volume149.15K
Shares Out.37.14M

COMPANY

LEADERSHIP

Joshua T. Brumm
CHIEF EXECUTIVE
Joshua T. Brumm

COMPENSATION 2026

Salary$638,405
Stock Awards$0
Incentive Plan Pay$376,910
All Other Comp.$10,775
Total$2,389,418

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 10, 2014
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
44

PRICE TARGET

Target High$35.00
Target Low$26.00
Target Median$32.00
Target Consensus$31.25

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$357.14K
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2025-06-16Reverse1:100

PRICE

$17.75 ▼ DOWN 0.06% (−$0.01)
OVERLAYS
$17.10$17.40$17.70$18.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM17.75

About Crescent Biopharma, Inc.

https://crescentbiopharma.com ↗

Crescent Biopharma, based in Waltham, MA, develops cancer therapies including CR-001, a bispecific antibody, through partnerships like Sichuan Kelun-Biotech, focusing on solid tumors and oncology therapeutics.

INDUSTRY

Biotechnology

A PRODUCT CRESCENT BIOPHARMA, INC. IS KNOWN FOR

CR-001
CR-001

CR-001 is Crescent Biopharma's investigational PD-1 x VEGF bispecific antibody for solid tumors, with the first patient dosed in the Phase 1/2 ASCEND trial as of February 2026.

COMPETITORS

COMPETITOR
BNTX COMPARE
EXEL COMPARE
INCY COMPARE
SMMT COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$30.6M — — —
Pharmaceutical Products— — — $29.1M
Reportable Segment— $8.05M $1.04M ▼—

ETFS HOLDING THIS STOCK

ETFS HOLDING
47
LISTED HERE
10
RANKED BY POSITION SIZE
VTI
0.00% · 906.6K
IWM
0.01% · 533.4K
R2US.L
0.01% · 40.2K
XRSG.L
0.01% · 19.8K
BBC
0.59% · 17.5K
RSSL
0.01% · 10.2K
AVSC
0.00% · 3.7K
URTY
0.00% · 877
RESM
0.01% · 41
SC0K.DE
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
55.97%
HOLDERS
84
TOP 12 OF 84 · RANKED BY POSITION SIZE
Fmr LLC
4.1M sh · $75.93M
Bvf Inc/Il
2.7M sh · $50.49M
Fairmount Funds Management LLC
2.7M sh · $32.59M
Vr Adviser, LLC
2.1M sh · $39.19M
Fcpm Iii Services B.V.
1.7M sh · $30.82M
Balyasny Asset Management L.P.
1.5M sh · $27.74M
Vestal Point Capital, LP
1.5M sh · $27.55M
Opaleye Management Inc.
1.3M sh · $24.11M
Tang Capital Management LLC
1.2M sh · $21.31M
Vanguard Group Inc
657.9K sh · $7.82M
Adar1 Capital Management, LLC
606.0K sh · $7.19M
Logos Global Management LP
600.0K sh · $7.13M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR, 10 PERCENT OWNER:
Fairmount Funds Management LLC
Purchase · 525.9K shares
2026-07-16
★
DIRECTOR, 10 PERCENT OWNER:
Fairmount Funds Management LLC
Purchase · 853.5K shares
2026-07-16
★
OFFICER: SEE REMARKS
Bispham Barbara Harlin
Sale · 1.2K shares
2026-06-22
★
OFFICER: SEE REMARKS
Lynch Ryan
Sale · 465 shares
2026-06-22

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. NEUTRAL

SECTORS PEERS

PEERPRICE
OABI$4.47COMPARE
CCCC$3.85COMPARE
CGEN$2.60COMPARE
TNXP$13.59COMPARE
IPHA$2.22COMPARE
IMDX$4.13COMPARE
HRTX$0.33COMPARE
HIND$2.21COMPARE